Beta Drugs Ltd

Beta Drugs Ltd Summary Chart Analysis Peers Quarters Profit & Loss Balance Sheet Cash Flow Ratios Investors Documents

Beta Drugs Ltd

₹ 1,774 0.67%
20 Jun - close price
Company website NSE - SME: BETA
About

Beta Drugs Ltd is engaged in manufacturing of a wide range of oncology (anti-cancer) drugs in India. It has operations in the domestic and export markets.[1]

Key Points

Market Position
The company is ranked among the top 10 oncology companies, and many of its key products are ranked among the top 5 in their respective categories. [1]

Website NSE - SM
  • Market Cap ₹ 1,791 Cr.
  • Current Price ₹ 1,774
  • High / Low ₹ 2,215 / 1,119
  • Stock P/E 95.5
  • Book Value ₹ 128
  • Dividend Yield 0.00 %
  • ROCE 16.1 %
  • ROE 15.3 %
  • Face Value ₹ 10.0
Edit ratios

Pros

  • Company's median sales growth is 21.6% of last 10 years

Cons

  • Stock is trading at 13.9 times its book value
  • Though the company is reporting repeated profits, it is not paying out dividend

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Edit Columns
Loading peers table ...

Half Yearly Results

Standalone Figures in Rs. Crores / View Consolidated

Sep 2019 Mar 2020 Sep 2020 Mar 2021 Sep 2021 Mar 2022 Sep 2022 Mar 2023 Sep 2023 Mar 2024 Sep 2024 Mar 2025
34 31 35 45 60 65 78 80 92 105 118 102
28 26 28 36 47 53 62 64 73 91 98 91
Operating Profit 7 5 7 9 13 13 16 15 19 14 20 11
OPM % 19% 16% 19% 19% 21% 19% 20% 19% 21% 14% 17% 11%
0 0 0 0 1 0 0 1 1 1 1 0
Interest 0 0 0 0 0 0 0 1 1 0 1 4
Depreciation 1 2 2 3 2 3 3 3 3 2 3 4
Profit before tax 6 3 4 6 10 10 13 12 16 13 18 3
Tax % 27% 10% 24% 33% 29% 30% 25% 26% 25% 26% 25% 29%
4 3 3 4 7 7 10 9 12 10 13 2
EPS in Rs 3.97 3.06 3.03 3.88 7.27 6.84 9.60 9.02 11.99 9.73 13.16 2.12
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
1 0 26 42 51 58 65 79 125 158 197 220
1 0 23 34 41 48 54 64 99 126 164 189
Operating Profit 0 0 3 7 9 10 12 15 25 31 34 31
OPM % 14% 0% 11% 17% 19% 18% 18% 19% 20% 20% 17% 14%
0 0 0 0 0 0 0 1 1 1 2 2
Interest 0 0 1 1 1 1 1 1 0 1 1 5
Depreciation 0 0 1 1 2 2 3 5 5 6 5 7
Profit before tax 0 -0 1 5 7 7 9 10 20 25 29 21
Tax % 0% 0% 0% 19% 1% -3% 21% 29% 29% 25% 26% 26%
0 -0 1 4 7 8 7 7 14 19 22 15
EPS in Rs -1.00 10.27 38.82 7.43 8.47 7.03 6.91 14.11 18.63 21.72 15.29
Dividend Payout % 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0% 0%
Compounded Sales Growth
10 Years: 96%
5 Years: 28%
3 Years: 21%
TTM: 12%
Compounded Profit Growth
10 Years: 67%
5 Years: 21%
3 Years: 10%
TTM: -15%
Stock Price CAGR
10 Years: %
5 Years: 98%
3 Years: 41%
1 Year: 55%
Return on Equity
10 Years: 19%
5 Years: 18%
3 Years: 19%
Last Year: 15%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity Capital 0.01 1 1 1 9 9 10 10 10 10 10 10
Reserves 0 0 1 5 24 32 47 54 68 87 106 119
1 5 8 8 8 8 9 5 7 6 6 124
0 2 5 9 9 16 17 18 27 32 49 64
Total Liabilities 1 8 15 23 50 65 82 86 111 134 170 317
1 1 7 8 13 12 32 28 34 35 36 53
CWIP 0 6 0 0 1 15 0 2 0 0 0 0
Investments 0 0 0 0 0 2 6 7 7 7 6 6
1 2 8 15 35 36 44 50 70 93 128 257
Total Assets 1 8 15 23 50 65 82 86 111 134 170 317

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
0 1 -0 5 17 8 6 12 19 10 21 18
0 -6 -2 -2 -11 -16 -14 -3 -13 -6 -11 -21
-0 4 3 -3 5 -1 9 -4 1 -2 -1 118
Net Cash Flow 0 0 0 0 12 -9 1 4 7 2 9 115

Ratios

Standalone Figures in Rs. Crores / View Consolidated

Mar 2014 Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Debtor Days 77 112 61 92 104 109 117 96 92 101 93 81
Inventory Days 123 3,115 69 37 38 76 64 65 44 60 71 84
Days Payable 34 5,256 97 108 82 121 97 111 101 102 116 124
Cash Conversion Cycle 166 -2,029 33 21 60 64 84 49 34 59 48 41
Working Capital Days 130 -758 34 50 75 70 87 83 63 83 72 68
ROCE % 10% -3% 22% 49% 29% 18% 17% 16% 27% 28% 27% 16%

Shareholding Pattern

Numbers in percentages

Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025
66.71% 66.71% 66.71% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73% 66.73%
0.00% 0.29% 0.29% 0.29% 0.29% 0.32% 0.32% 0.32% 0.90% 1.16% 1.15% 0.90%
0.29% 0.04% 0.04% 0.04% 0.04% 0.02% 0.02% 0.06% 0.12% 0.16% 0.17% 0.17%
33.00% 32.96% 32.96% 32.94% 32.93% 32.93% 32.92% 32.87% 32.25% 31.95% 31.95% 32.20%
No. of Shareholders 1,2961,4071,4441,4241,4511,7221,9282,1162,3232,5672,8823,054

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

Annual reports

DRHP

Credit ratings

Concalls